MAYNE PHARMA GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.12 AUD | +4.25% |
|
+2.30% | +15.77% |
| Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
| Feb. 25 | Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024 |
| Sales 2024 * | 384M 248M | Sales 2025 * | 429M 277M | Capitalization | 554M 357M |
|---|---|---|---|---|---|
| Net income 2024 * | -83M -53.53M | Net income 2025 * | -2M -1.29M | EV / Sales 2024 * | 1.25 x |
| Net cash position 2024 * | 72.1M 46.5M | Net cash position 2025 * | 60.91M 39.28M | EV / Sales 2025 * | 1.15 x |
| P/E ratio 2024 * |
-6.67
x | P/E ratio 2025 * |
-199
x | Employees | 967 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mayne Pharma Group Limited
More press releases
| 1 day | +4.25% | ||
| 1 week | +4.71% | ||
| Current month | -1.66% | ||
| 1 month | +4.25% | ||
| 3 months | +37.98% | ||
| 6 months | +95.60% | ||
| Current year | +15.77% |
1 week
6.50
7.18
1 month
6.507.40
Current year
5.007.40
1 year
2.757.40
3 years
0.229.10
5 years
0.2214.80
10 years
0.2242.20
| Managers | Title | Age | Since |
|---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Aaron Gray
DFI | Director of Finance/CFO | - | 22-08-28 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 18-05-29 |
Patrick Blake
BRD | Director/Board Member | 59 | 18-06-27 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 7.12 | +4.25% | 197 322 |
| 24-04-22 | 6.83 | +2.55% | 246,992 |
| 24-04-19 | 6.66 | -1.33% | 130,562 |
| 24-04-18 | 6.75 | +1.35% | 105,398 |
| 24-04-17 | 6.66 | -2.06% | 79,559 |
Delayed Quote Australian S.E., April 23, 2024 at 02:10 am EDT
More quotes
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.83
AUD
Average target price
7.035
AUD
Spread / Average Target
+3.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.77% | 357M | |
| +17.88% | 44.31B | |
| +19.87% | 22.17B | |
| +14.93% | 14.62B | |
| +8.06% | 13.12B | |
| +39.21% | 11.58B | |
| -8.96% | 6.96B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.50% | 5.03B |
- Stock Market
- Equities
- MYX Stock
